Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (EMPRESS) Trial

NCT06184659 is registered in ClinicalTrials.gov with Scandinavian Critical Care Trials Group as lead sponsor.

NCT NCT06184659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06184659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (EMPRESS) Trial
Lead sponsor
Scandinavian Critical Care Trials Group
Phase
Phase 4
Overall status
Recruiting
Start date
June 26, 2025
Completion date
March 30, 2029
Enrollment
5,800 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

sepsis, septic shock